SENIOR SCIENTIST, MEMBER OF CONGREGATION AND SUPERVISOR
Vaccine Formulation Group
I studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford, UK. In 2009 I joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility. I now lead the Vaccine Formulation Group, focusing on vaccine adjuvant development in the context of malaria vaccines, with a key emphasis on the adjuvant mechanism of action. Additionally, in collaboration with the Institute for Biomedical Engineering (IBME), we are developing new microfluidics-based vaccine encapsulation technologies for controlled vaccine release. The aim is to achieve single-dose immunisation that could replace the standard prime-boost approach: the booster vaccine is encapsulated into microcapsules and delivered together with the prime, for delayed release within the body.
My overall interest is in the mechanisms of immune activation, in particular the interplay between the innate and the adaptive immunity. Vaccine development, with a focus on vaccine adjuvants, provides the ideal base for such studies. My current research includes exploring the mechanism of action of adjuvanted vaccines using different vaccine platforms and clinically-compatible adjuvants developed by the Vaccine Formulation Institute (VFI) in Geneva.
Following a long-standing collaboration with the VFI, in late 2019 we initiated the VFI-Oxford Adjuvant Programme of research with three primary aims: a) understand the types of responses induced by different clinically-compatible adjuvants, b) characterise the adjuvant immunogenicity profiles using clinically relevant antigens and c) assess vaccine efficacy through challenge studies in pre-clinical models of disease. These questions are being addressed through spatio-temporal studies of the innate and adaptive immune responses to adjuvanted vaccines, using an established mouse model of malaria.
I am a Core Group member and Working Group leader in the EU COST Action Programme ENOVA (European Network of Vaccine Adjuvants; www.enova-adjuvant.eu). I am also the Jenner Institute lead for Public Engagement with Research.
Publisher Correction: Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria.
Milicic A. et al, (2019), Scientific reports, 9
Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease
Elshina E. et al, (2019), Vaccine, 37, 502 - 509
Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]
Coughlan L. et al, (2018), EBioMedicine, 31, 321 - 321
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
Coughlan L. et al, (2018), EBioMedicine, 29, 146 - 154
Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
Milicic A. et al, (2017), Scientific Reports, 7